Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040180304> ?p ?o ?g. }
- W2040180304 endingPage "480.e2" @default.
- W2040180304 startingPage "471" @default.
- W2040180304 abstract "ObjectiveCell-based gene therapy can enhance the effects of cell transplantation by temporally and spatially regulating the release of the gene product. The purpose of this study was to evaluate transient matrix metalloproteinase inhibition by implanting cells genetically modified to overexpress a natural tissue inhibitor of matrix metalloproteinases (tissue inhibitor of matrix metalloproteinase-3) into the hearts of mutant (tissue inhibitor of matrix metalloproteinase-3–deficient) mice that exhibit an exaggerated response to myocardial infarction. Following a myocardial infarction, tissue inhibitor of matrix metalloproteinase-3–deficient mice undergo accelerated cardiac dilatation and matrix disruption due to uninhibited matrix metalloproteinase activity. This preliminary proof of concept study assessed the potential for cell-based gene therapy to reduce matrix remodeling in the remote myocardium and facilitate functional recovery.MethodsAnesthetized tissue inhibitor of matrix metalloproteinase-3–deficient mice were subjected to coronary ligation followed by intramyocardial injection of vector-transfected bone marrow stromal cells, bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3, or medium. Functional, morphologic, histologic, and biochemical studies were performed 0, 3, 7, and 28 days later.ResultsBone marrow stromal cells and bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 significantly decreased scar expansion and ventricular dilatation 28 days after coronary ligation and increased regional capillary density to day 7. Only bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 reduced early matrix metalloproteinase activities and tumor necrosis factor α levels relative to medium injection. Bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 were also more effective than bone marrow stromal cells in preventing progressive cardiac dysfunction, preserving remote myocardial collagen content and structure, and reducing border zone apoptosis for at least 28 days after implantation.ConclusionsTissue inhibitor of matrix metalloproteinase-3 overexpression enhanced the effects of bone marrow stromal cells transplanted early after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3–deficient mice by contributing regulated matrix metalloproteinase inhibition to preserve matrix collagen and improve functional recovery. Cell-based gene therapy can enhance the effects of cell transplantation by temporally and spatially regulating the release of the gene product. The purpose of this study was to evaluate transient matrix metalloproteinase inhibition by implanting cells genetically modified to overexpress a natural tissue inhibitor of matrix metalloproteinases (tissue inhibitor of matrix metalloproteinase-3) into the hearts of mutant (tissue inhibitor of matrix metalloproteinase-3–deficient) mice that exhibit an exaggerated response to myocardial infarction. Following a myocardial infarction, tissue inhibitor of matrix metalloproteinase-3–deficient mice undergo accelerated cardiac dilatation and matrix disruption due to uninhibited matrix metalloproteinase activity. This preliminary proof of concept study assessed the potential for cell-based gene therapy to reduce matrix remodeling in the remote myocardium and facilitate functional recovery. Anesthetized tissue inhibitor of matrix metalloproteinase-3–deficient mice were subjected to coronary ligation followed by intramyocardial injection of vector-transfected bone marrow stromal cells, bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3, or medium. Functional, morphologic, histologic, and biochemical studies were performed 0, 3, 7, and 28 days later. Bone marrow stromal cells and bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 significantly decreased scar expansion and ventricular dilatation 28 days after coronary ligation and increased regional capillary density to day 7. Only bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 reduced early matrix metalloproteinase activities and tumor necrosis factor α levels relative to medium injection. Bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3 were also more effective than bone marrow stromal cells in preventing progressive cardiac dysfunction, preserving remote myocardial collagen content and structure, and reducing border zone apoptosis for at least 28 days after implantation. Tissue inhibitor of matrix metalloproteinase-3 overexpression enhanced the effects of bone marrow stromal cells transplanted early after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3–deficient mice by contributing regulated matrix metalloproteinase inhibition to preserve matrix collagen and improve functional recovery." @default.
- W2040180304 created "2016-06-24" @default.
- W2040180304 creator A5026006836 @default.
- W2040180304 creator A5037975827 @default.
- W2040180304 creator A5049131213 @default.
- W2040180304 creator A5050113317 @default.
- W2040180304 creator A5056544915 @default.
- W2040180304 creator A5058720741 @default.
- W2040180304 creator A5063942792 @default.
- W2040180304 creator A5071798015 @default.
- W2040180304 creator A5073547801 @default.
- W2040180304 creator A5087710458 @default.
- W2040180304 date "2009-02-01" @default.
- W2040180304 modified "2023-10-16" @default.
- W2040180304 title "Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3–deficient mice" @default.
- W2040180304 cites W16158435 @default.
- W2040180304 cites W1819055812 @default.
- W2040180304 cites W1977111128 @default.
- W2040180304 cites W1988508537 @default.
- W2040180304 cites W1997522892 @default.
- W2040180304 cites W1998537251 @default.
- W2040180304 cites W2021625203 @default.
- W2040180304 cites W2026611301 @default.
- W2040180304 cites W2037791649 @default.
- W2040180304 cites W2041119309 @default.
- W2040180304 cites W2053060883 @default.
- W2040180304 cites W2065755593 @default.
- W2040180304 cites W2077148065 @default.
- W2040180304 cites W2091453633 @default.
- W2040180304 cites W2098234683 @default.
- W2040180304 cites W2107726585 @default.
- W2040180304 cites W2107984202 @default.
- W2040180304 cites W2107994885 @default.
- W2040180304 cites W2112767296 @default.
- W2040180304 cites W2112976455 @default.
- W2040180304 cites W2123503904 @default.
- W2040180304 cites W2124894661 @default.
- W2040180304 cites W2129172826 @default.
- W2040180304 cites W2143321915 @default.
- W2040180304 cites W2146555081 @default.
- W2040180304 cites W2147844320 @default.
- W2040180304 cites W2148219033 @default.
- W2040180304 cites W2152040897 @default.
- W2040180304 cites W2155015866 @default.
- W2040180304 cites W2158682140 @default.
- W2040180304 cites W2167935048 @default.
- W2040180304 doi "https://doi.org/10.1016/j.jtcvs.2008.08.031" @default.
- W2040180304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19185172" @default.
- W2040180304 hasPublicationYear "2009" @default.
- W2040180304 type Work @default.
- W2040180304 sameAs 2040180304 @default.
- W2040180304 citedByCount "24" @default.
- W2040180304 countsByYear W20401803042012 @default.
- W2040180304 countsByYear W20401803042013 @default.
- W2040180304 countsByYear W20401803042014 @default.
- W2040180304 countsByYear W20401803042016 @default.
- W2040180304 countsByYear W20401803042017 @default.
- W2040180304 countsByYear W20401803042020 @default.
- W2040180304 crossrefType "journal-article" @default.
- W2040180304 hasAuthorship W2040180304A5026006836 @default.
- W2040180304 hasAuthorship W2040180304A5037975827 @default.
- W2040180304 hasAuthorship W2040180304A5049131213 @default.
- W2040180304 hasAuthorship W2040180304A5050113317 @default.
- W2040180304 hasAuthorship W2040180304A5056544915 @default.
- W2040180304 hasAuthorship W2040180304A5058720741 @default.
- W2040180304 hasAuthorship W2040180304A5063942792 @default.
- W2040180304 hasAuthorship W2040180304A5071798015 @default.
- W2040180304 hasAuthorship W2040180304A5073547801 @default.
- W2040180304 hasAuthorship W2040180304A5087710458 @default.
- W2040180304 hasBestOaLocation W20401803041 @default.
- W2040180304 hasConcept C104317684 @default.
- W2040180304 hasConcept C106487976 @default.
- W2040180304 hasConcept C109523444 @default.
- W2040180304 hasConcept C111599444 @default.
- W2040180304 hasConcept C126322002 @default.
- W2040180304 hasConcept C142724271 @default.
- W2040180304 hasConcept C16930146 @default.
- W2040180304 hasConcept C185592680 @default.
- W2040180304 hasConcept C2775958869 @default.
- W2040180304 hasConcept C2775965246 @default.
- W2040180304 hasConcept C2780007613 @default.
- W2040180304 hasConcept C2910007452 @default.
- W2040180304 hasConcept C43617362 @default.
- W2040180304 hasConcept C502942594 @default.
- W2040180304 hasConcept C55493867 @default.
- W2040180304 hasConcept C71924100 @default.
- W2040180304 hasConcept C86803240 @default.
- W2040180304 hasConceptScore W2040180304C104317684 @default.
- W2040180304 hasConceptScore W2040180304C106487976 @default.
- W2040180304 hasConceptScore W2040180304C109523444 @default.
- W2040180304 hasConceptScore W2040180304C111599444 @default.
- W2040180304 hasConceptScore W2040180304C126322002 @default.
- W2040180304 hasConceptScore W2040180304C142724271 @default.
- W2040180304 hasConceptScore W2040180304C16930146 @default.
- W2040180304 hasConceptScore W2040180304C185592680 @default.
- W2040180304 hasConceptScore W2040180304C2775958869 @default.
- W2040180304 hasConceptScore W2040180304C2775965246 @default.
- W2040180304 hasConceptScore W2040180304C2780007613 @default.